Biodexa Announces $7M Of Gross Proceeds From Warrant Exercises And An Agreement Between The Company And Several Accredited Investors To Exercise Certain Existing Series E Warrants And Series F Warrants To Purchase Up To An Aggregate Of 4,358,322 ADSs
Biodexa Announces $7M Of Gross Proceeds From Warrant Exercises And An Agreement Between The Company And Several Accredited Investors To Exercise Certain Existing Series E Warrants And Series F Warrants To Purchase Up To An Aggregate Of 4,358,322 ADSs
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
Biodexa宣佈認股權證行使的總收益爲700萬美元
Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding
所得款項用於支付第一年 eRapa 第 3 階段的債務，解鎖該金額的兩倍非攤薄補助資金
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E warrants ("Series E Warrants") and Series F warrants ("Series F Warrants," and together with the Series E Warrants, the "Existing Warrants") to purchase up to an aggregate of 4,358,322 of the Company's American Depositary Shares ("ADSs) (each ADS represents 400 ordinary shares, nominal value £0.001 of the Company ("Ordinary Shares")).
Biodexa Pharmicals PLC（納斯達克股票代碼：BDRX）是一家專注於收購的臨床階段生物製藥公司，開發一系列用於治療醫療需求未得到滿足的疾病的創新產品。該公司宣佈，行使先前發行的認股權證將獲得700萬美元的總收益，以及公司與幾位合格投資者達成協議，以行使某些現有的E系列認股權證（“E系列認股權證”）和F系列認股權證（“F系列認股權證”）和F系列認股權證（“F系列認股權證”）”，以及E系列認股權證（“現有認股權證”），最多可購買公司的美國存托股份（“ADS”）共計4,358,322股（每股ADS代表公司的400股普通股，名義價值0.001英鎊（“普通股”））。
譯文內容由第三人軟體翻譯。